Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
According to Precipio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.56. At the end of 2022 the company had a P/S ratio of 1.33.
Year | P/S ratio |
---|---|
2023 | 0.56 |
2022 | 1.33 |
2021 | 3.77 |
2020 | 5.60 |
2019 | 3.73 |
2018 | 1.16 |
2017 | 3.23 |
2016 | 0.08 |
2015 | 2.24 |
2014 | 1.66 |
2013 | 1.58 |
2012 | 1.10 |
2011 | 0.77 |
2010 | 1.23 |
2009 | 1.12 |
2008 | 1.03 |
2007 | 1.06 |
2006 | 1.05 |
2005 | 0.69 |
2004 | 0.43 |
2003 | 0.36 |
2002 | 0.31 |
2001 | 0.29 |
2000 | 0.32 |
1999 | 0.28 |